艾地苯醌联合倍他司汀治疗脑梗死后认知功能障碍的临床疗效

Clinical Efficacy of Combination Therapy of Esomeprazole and Betamethasone in the Treatment of Cognitive Impairment after Cerebral Infarction

主要研究脑梗死后认知障碍患者治疗中采取艾地苯醌联合倍他司汀治疗的临床效果。选择我院2021年1月-2022年12月收治的50例脑梗死后认知障碍患者为观察对象,采用随机数字法分为观察组和对照组,每组25例,观察组采取艾地苯醌联合倍他司汀治疗,对照组采取常规治疗,比较两组治疗后临床疗效、不良反应发生率,血清学指标[超氧化物歧化酶(SOD)、胰岛素样生长因子1(IGF-1)及脑源性神经营养因子(BDNF)]、认知功能[简易智能精神状态检查量表(MMSE)、蒙特利尔认知评估量表(MoCA)]、神经功能[去甲肾上腺素(NE)、乙酰胆碱(ACh)]。结果表明,观察组的有效率(92%)优于对照组(68%),差异有统计学意义(P<0.05);神经功能、认知功能及血清学指标水平比较,两组治疗前差异均无统计学意义(P>0.05),两组治疗后的SOD水平较治疗前降低,IGF-1及BDNF水平较治疗前升高,且观察组治疗后的SOD低于对照组,IGF-1及BDNF水平高于对照组,差异有统计学意义(P<0.05);治疗后,两组MMSE、MoCA得分较治疗前升高,且观察组的MMSE、MoCA得分高于对照组,差异有统计学意义(P<0.05);治疗后,两组的NE、ACh水平较治疗前升高,且观察组的NE、ACh水平均高于对照组,差异有统计学意义(P<0.05)。得出在脑梗死后认知功能障碍治疗中采取艾地苯醌联合倍他司汀治疗可提高临床治疗效果,改善神经功能与认知功能,较常规治疗措施更有助于减轻氧自由基对人体的损害,提高免疫功能,同时还能对神经提供蛋白质营养作用,值得推广。

This article mainly studies the clinical efficacy of using a combination of esomeprazole and betamethasone in the treatment of cognitive impairment patients after cerebral infarction,as well as their impact on SOD,IGF-1,and BDNF levels.Fifty patients with cognitive impairment after cerebral infarction admitted to our hospital from January 2021 to December 2022 were selected as the observation subjects.They were randomly divided into an observation group and a control group,with 25 cases in each group.The observation group received treatment with combination of esomeprazole and betamethasone,while the control group received conventional treatment.The clinical efficacy,incidence of adverse reactions,serological indicators[superoxide dismutase(SOD),insulin-like growth factor-1(IGF-1),and brain-derived neurotrophic factor(BDNF)],cognitive function[Mini Intelligent Mental State Examination(MMSE),Montreal Cognitive Assessment Scale(MoCA)],and neurological function were compared between the two groups.Norepinephrine(NE),acetylcholine(ACh).The effective rate of the observation group(92%)was better than that of the control group(68%),and the difference was statistically significant(P<0.05);The comparison of neurological function,cognitive function,and serological indicators showed no statistically significant difference between the two groups before treatment(P>0.05).The SOD levels of the two groups decreased after treatment,while the levels of IGF-1 and BDNF increased before treatment.Moreover,the SOD levels of the observation group were lower than those of the control group,while the levels of IGF-1 and BDNF were higher than those of the control group,and the difference was statistically significant(P<0.05);After treatment,the cognitive function scale scores of the two groups increased compared to before treatment,and the MMSE and MoCA of the observation group were higher than those of the control group,with statistical significance(P<0.05);After treatment,the neurological function indicators of the two groups increased compared to before treatment,and the NE and ACh of the observation group were higher than those of the control group,with statistical significance(P<0.05).Conclusion:In the treatment of cognitive impairment after cerebral infarction,the combination of esomeprazole and betamethasone can improve clinical efficacy,improve neurological and cognitive function,and is more helpful in reducing the damage of oxygen free radicals to the human body,improving immune function,and providing protein nutrition to the nerves.It is worth promoting.